



TFW

PATENT APPLICATION

Our File No.: 20040117.ORI

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re App : Stephen Hart et al : September 27, 2004
S.N. : 10/824,584 : Art Unit unknown
Filed : April 8, 2004
For : CONTROL OF GENE EXPRESSION USING
A COMPLEX OF AN OLIGONUCLEOTIDE AND
A REGULATORY PEPTIDE

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER RULE 1.56

Applicant(s) herein make available to the Patent and Trademark Office a copy of Form PTO-1449 which lists the following document(s), copies of which are enclosed. This Information Disclosure Statement is being filed in accordance with the following provision(s):

- ☐ 37 CFR 1.97(b)(1) Within three months of the filing date of the national application. No fee is required.
- ☐ 37 CFR 1.97(b)(2) Within three months of the date of entry of the national stage as set forth in § 1.491 in the international application. No fee is required.
- ☒ 37 CFR 1.97(b)(3) Before the mailing date of a first Office Action on the merits. No fee is required.
- ☐ 37 CFR 1.97(c) After the periods specified in 37 CFR 1.97(b), but before the mailing date of either: (1) a

final action under § 1.113 or (2) a notice of allowance under § 1.311, whichever occurs first.

- [] The undersigned hereby certifies that each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement; or
- [] The undersigned hereby certifies that no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned after making reasonable inquiry, was known to any individual designated in § 1.56(c) more than three months prior to the filing of this statement; or
- [] Enclosed is a check in the amount of \$200.00 for the fee set forth in 37 CFR § 1.17(p). The Commissioner is hereby authorized to charge any additional fees which may be required under 37 C.F.R. 1.17, or credit any overpayment, to Deposit Account No. 08-1265. Two copies of this sheet are enclosed.
- [] 37 CFR 1.97(d) After the mailing date of either (1) a final action under § 1.113 or (2) a notice of allowance under § 1.311, whichever occurs first, but before payment of the issue fee.
- [] Applicant(s) hereby petition the Commissioner of Patents and Trademarks to consider this information disclosure statement. Enclosed is a check in the amount of \$130.00 for the petition fee set forth in § 1.17(i)(1). The Commissioner is hereby authorized to charge any additional fees which may be required under 37 C.F.R. 1.17, or credit any overpayment, to Deposit Account No. 08-1265. Two copies of this sheet are enclosed.

The Examiner is requested to consider carefully the complete text of these documents in connection with the examination of the above-identified application in accordance with 37 CFR 1.104(a).

It is requested that the documents listed on the attached Form PTO-1449 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. 1302.12), and that the Examiner initial and return a copy of the form to evidence consideration of the documents.

Dated: September 27, 2004. Respectfully submitted,

NIKOLAI & MERSEREAU, P.A.



C. G. Mersereau
Attorney for Applicant(s)
Registration No. 26,205
900 Second Avenue South
Suite 820
Minneapolis, MN 55402
Phone: 612-339-7461


CERTIFICATE OF MAILING

I hereby certify that the foregoing Supplemental Information Disclosure Statement Under Rule 1.56, Form PTO-1449 and a copy of each cited reference to be filed in connection with application Serial No. 10/824,584 of inventors, Stephen Hart et al, filed April 8, 2004, for " CONTROL OF GENE EXPRESSION USING A COMPLEX OF AN OLIGONUCLEOTIDE AND A REGULATORY PEPTIDE " are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on September 28, 2004.



Barbara L. Davis
Secretary to C. G. Mersereau

Date of Signature: September 28, 2004



Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)	Document Number 20040117.ORI	Application Number 10/824,584
	Applicant Stephen Hart et al	
	Filing Date April 8, 2004	Group Art Unit Unknown

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
					YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Papers, Etc.)

	Ayer et al, CELL, Mad: A Heterodimeric Partner for Max That Antagonizes Myc Transcriptional Activity, Vol. 72, January 29, 1993, pp. 211-222
	Ayer et al, CELL, Mad-Max Transcriptional Repression is Mediated by Ternary Complex Formation with Mammalian Homologs of Yeast Repressor Sin3, Vol. 80, March 10, 1995, pp. 767-776
	Chen et al, NATURE, SA Transcriptional Co-Repressor that Interacts with Nuclear Hormone Receptors, Vol. 377, 1995, pp. 454-457
	Dangond et al, BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, Differential Display Cloning of a Novel Human Histone Deacetylase (HDAC3) cDNA from PHA-Activated Immune Cells, Vol. 242, 1998, pp. 648-652
	Eritia et al, TETRAHEDRON, Synthesis of Defined Peptide-Oligonucleotide Hybrids Containing a Nuclear Transport Signal Sequence, Vol. 47, 1991, pp. 4113-4120
	Lechner et al, BIOCHIM. BIOPHYS. ACTA, A Comparative Study of Histone Deacetylases of Plant, Fungal and Vertebrate Cells, Vol. 1296, 1996, pp. 181-188
	Okano et al, NATURE GENETICS, Cloning and Characterization of a Family of Novel Mammalian DNA (Cytosine-5) Methyltransferases, Vol. 19, July 1998, pp. 219-220
	Prochiantz, CURRENT OPINION CELL BIOLOGY, Messenger Proteins: Homeoproteins, TAT and Others, Vol. 9, 2000, pp. 400-406
	Qian et al, NATURE, A Retinoblastoma-Binding Protein Related to a Negative Regulator of Ras in Yeast, Vol. 364, 1993, pp. 648-652

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)	Document Number 20040117.ORI	Application Number 10/824,584
	Applicant Stephen Hart et al	
	Filing Date April 8, 2004	Group Art Unit Unknown

U. S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Papers, Etc.)

		Schreiber-Agus et al, CELL, <i>An Amino-Terminal Domain of Mx1 Mediates Anti-Myc Oncogenic Activity and Interacts with a Homolog of the Yeast Transcriptional Repressor SIN3</i> , Vol. 80, 1995, pp. 777-786
		Taunton et al, NATURE, <i>A Mammalian Histone Deacetylase Related to the Yeast Transcriptional Regulator Rpd3p</i> , Vol. 272, (1996), pp. 408-441
		Tommasino and Crawford, BIOESSAYS, <i>Human Papillomavirus E6 and E7: Proteins which Deregulate the Cell Cycle</i> , Vol.17, 1995, pp. 509-518
		Weinberg, CELL, <i>The Retinoblastoma Protein and Cell Cycle Control</i> , Vol. 81, (1995) pp. 323-330
		Giovannangeli et al, NUCLEIC ACIDS RESEARCH, <i>Oligodeoxynucleotide-Directed Photo-induced Cross-linking of HIV Proviral DNA Via Triple-Helix Formation</i> , Vol. 20, No. 16, 1992, pp. 4275-4281

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.